Current targeted therapy of breast cancer is strongly associated with the term receptor tyrosine kinase. All agents of this new world of antineoplastic therapy that have been approved so far are directed against members of this receptor superfam-ily. The clinical significance of targeted therapy is defined by synergistic effects with conventional chemotherapy. The HER2-targeted therapy shows that inhibition of a single receptor can be highly efficient in the treatment of breast cancer. However, limitations of the first generation of targeted treatment are apparent by the example of the HER2 antibody trastuzumab.
展开▼
